ECTRIMS Congress 2026: key results and trends

Relapses occurred in 6 (9%) participants receiving tocilizumab plus prednisone treatment and 18 (53%) receiving prednisone treatment alone (hazard ratio 0.13 [95% CI 0.05-0.33], p<0.0001).

NEDA-3 was achieved by 80.2% (69/86) vs 43.7% (31/71) participants with OMB vs cFL-DMT (odds ratio: 5.02, p<0.001).

When the time to first adjudicated relapse or first use of rescue therapy was analyzed, satralizumab reduced the risk of relapse by 63% compared with placebo (HR: 0.37, 95% CI: 0.19–0.73; p=0.0025).

Relapses occurred in 17 patients (19%) receiving daratumumab and in 27 (60%) receiving placebo (hazard ratio, 0.26; 95% confidence interval [CI], 0.14 to 0.47; p<0.0001).

FEN significantly reduced risk of disease activity vs TFM per NEDA-3 (HR, 0.30; 95% CI 0.25-0.35; P<0.001).

CDP 24 at year 7 was 11.7% in UBL-UBL vs 17.4% in TER-UBL patients [HR (95% CI): 0.65 (0.46, 0.92); P=0.015].

During the core period, at week 108, ponesimod reduced the risk of disability accumulation versus teriflunomide for 12w cCDA (23.4% vs 31.1%; HR 0.75 [0.59–0.95]).

Serious adverse events were similar and occurred in 6.8% and 7.1%, respectively, whereas infections were more frequent with rituximab (81.8% vs. 69.0%).

In the indirect comparison, divozilimab was associated with a significant reduction in risk of relapse versus historical placebo (weighted HR 0.108; 95% CI 0.036-0.324; p<0.001).

An ≥8-point MFIS response occurred in 71.2% on ketamine compared with 37.8% on midazolam (adjusted odds ratio, 4.55; 95% CI, 1.91–10.87; p<0.001).

CDI events occurred more frequently in the VidoCa-VidoCa group versus PBO-VidoCa (HR: 2.84, p=0.008).

For key secondary endpoints in the ITT analysis, the IVMP+Ecu group showed greater reduction in OSIS (2.55 vs. 1.12, mean difference, 1.42; 95% CI, 0.48-2.36; P<0.005) and EDSS (0.99 vs. 0.36, mean difference, 0.63; 95% CI, 0.24-1.01; P<0.005) compared to IVMP at Day 28.